Showcasing Initiatives to Advance the Use of Medical Data in AI, Including Its First AI Theater Presentation and a Scientific Poster Presentation
Medical AI Promotion Institute Co., Ltd. (Headquarters: Chuo-ku, Tokyo; Representative Directors: Yuki Shimahara and Sho Kawabe; hereinafter referred to as “MAPI”) will exhibit at the 112th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA 2026), the world’s largest radiology conference, to be held in Chicago, USA, from November 29 (Sunday) to December 3 (Thursday), 2026. This marks MAPI’s third consecutive year exhibiting at RSNA.
This year’s participation will be MAPI’s first since obtaining certification under Japan’s Next Generation Medical Infrastructure Act in September 2026 (*1). In addition to showcasing its services at the exhibition booth, MAPI will deliver its first presentation at the AI Theater and present its research findings as a Scientific Poster.
Exhibition Highlights
Under the theme “Make Your Medical AI Work in Japan,” MAPI will introduce its support services for international medical AI companies seeking to develop and commercialize their products in Japan, focusing on three key areas.
Exhibition Booth: 5931 (South Hall A, Level 3)
1. Data Collection and Proof of Concept (PoC)
Leveraging its nationwide network of partner medical institutions, MAPI supports retrospective data collection (*2), prospective studies (*3), and coordination with medical institutions for PoC implementation.
2. Data Processing
MAPI offers “MAPI GATEWAY,” an on-premises medical imaging de-identification support system that enables the extraction and anonymization of medical imaging data within healthcare institutions.
MAPI also provides image-level de-identification services, including de-facing, re-facing, and removal of burned-in text from medical images (*4).
Additional services include image annotation by in-house board-certified radiologists (*5) and outsourced anonymization of existing medical datasets.
3. Regulatory Affairs and Commercialization
MAPI provides comprehensive support for bringing medical AI products to market in Japan, including the development of PMDA and FDA regulatory strategies, performance evaluation studies for diagnostic imaging devices, preparation of regulatory submission documents, and support for PMDA consultations.
MAPI also assists with business planning, market analysis, and sales strategy development to support successful commercialization in Japan.
AI Theater Presentation
For the first time, MAPI will deliver a presentation at the AI Theater, a dedicated presentation area within the RSNA exhibition where participating companies introduce AI-related technologies.
Medical images accumulated in hospitals cannot be used directly for AI development without extensive preparation. Multiple processes are required, including data extraction and organization, linkage with other systems, quality control, and protection of personal information.
In this session, MAPI will introduce its practical workflows for transforming hospital data into AI-ready datasets. Topics will include on-premises data processing without transferring data outside hospitals, de-identification of both DICOM metadata and image content, and methods for evaluating the effectiveness of de-identification.
Session Details
※Please note that the AI Theater presentation venue (Booth 5536) is different from MAPI’s exhibition booth (Booth 5931).
Scientific Poster Presentation
MAPI will present its research findings on latent information contained in chest radiographs (*6) as a Scientific Poster.
Presentation Details
MAPI’s Initiatives
MAPI operates across three core business areas to advance the real-world implementation of medical AI: next-generation medical database services, AI research and development, and medical AI commercialization support.
In September 2026, MAPI obtained certification as both a Certified Business Operator for the Preparation of Anonymized Medical Information and a Certified Business Operator for the Preparation of Pseudonymized Medical Information under Japan’s Next Generation Medical Infrastructure Act.
This certification has enabled MAPI to establish a framework for preparing and providing clinical information, including medical images and videos accumulated at healthcare institutions, as datasets suitable for research and development.
MAPI also aims to build a global ecosystem that facilitates the development and adoption of diverse medical AI technologies by supporting Japanese medical AI startups in expanding overseas and international companies entering the Japanese market.
MAPI will continue to promote the utilization of medical data and medical AI research in Japan, contributing to a future where AI is seamlessly integrated into everyday clinical practice and a wide range of high-quality medical AI solutions are widely available.
RSNA 2026 Event Overview
Inquiries Regarding the Exhibition
For inquiries regarding MAPI’s exhibition or to arrange a meeting during RSNA 2026, please contact:
Email: contact@mapi-jp.org
Notes
(*1) October 1, 2026: “Medical AI Promotion Institute Obtains Certification Under Japan’s Next Generation Medical Infrastructure Act”
https://prtimes.jp/main/html/rd/p/000000025.000135533.html
(*2) Collection of data that has already been acquired and accumulated during past clinical practice.
(*3) Research involving the collection and analysis of clinical data generated after the initiation of a study, in accordance with a predefined research protocol.
(*4) De-facing: A process that removes facial regions from head images.
Re-facing: A process that replaces facial regions with alternative facial appearances, making individual identification more difficult while preserving the utility of the images.
Removal of burned-in text: A process that removes identifying information, such as names and IDs, embedded directly within medical images.
(*5) The process of adding ground-truth labels or annotations to images for AI training.
(*6) August 28, 2026: “Research Findings on Latent Information Contained in Chest Radiographs Accepted as a Scientific Poster at RSNA 2026, the World’s Largest Radiology Conference”
https://prtimes.jp/main/html/rd/p/000000022.000135533.html
Company Overview
Company Name: Medical AI Promotion Institute Co., Ltd. (MAPI)
Representative Directors: Yuki Shimahara and Sho Kawabe
Headquarters: 4F, Nihonbashi Life Science Building 9, 12-9 Nihonbashi-Odemmacho, Chuo-ku, Tokyo, Japan
Established: November 8, 2023
Business Activities: Development and operation of a next-generation medical database for the processing and sale of medical data
Website: https://mapi-jp.org
Facebook: https://www.facebook.com/iryoaisuishinkiko
X: https://x.com/iryoai_mapi
Media Contact
Public Relations, Medical AI Promotion Institute
Email: pr@mapi-jp.org
